Monday, August 12, 2019
CMS last week finalized its decision to cover...
...CAR-T cell treatments, as well as all services related to
administration of the costly therapy. Available CAR-T therapies have been slow
to pick up coverage due to their high list prices, with Gilead's Yescarta
priced at $373,000 and Novartis' Kymriah at $475,000. CMS currently facilitates
coverage for 33,301,406 people through Medicare fee-for-service.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment